First in Human and Early Stage Clinical Trials of Novel Investigational Drugs for Psychiatric Disorders (U01)
The summary for the First in Human and Early Stage Clinical Trials of Novel Investigational Drugs for Psychiatric Disorders (U01) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
First in Human and Early Stage Clinical Trials of Novel Investigational Drugs for Psychiatric Disorders (U01): The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action, investigational drugs or drug candidates for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase Ib studies of novel Agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. PoC studies must evaluate the drugs impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports feasibility and pilot studies of novel devices. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, devices or combination treatments in order to attract private funding for further clinical development as FDA-approved treatments. A key aspect of this FOA is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development.
Federal Grant Title: | First in Human and Early Stage Clinical Trials of Novel Investigational Drugs for Psychiatric Disorders (U01) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | PAR-14-107 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.242 |
CFDA Descriptions: | Mental Health Research Grants |
Current Application Deadline: | May 7, 2017 |
Original Application Deadline: | May 7, 2017 |
Posted Date: | Feb 24, 2014 |
Creation Date: | Feb 24, 2014 |
Archive Date: | Jun 7, 2017 |
Total Program Funding: | |
Maximum Federal Grant Award: | none |
Minimum Federal Grant Award: | none |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- County governments
Small businesses
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
For profit organizations other than small businesses
Independent school districts
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
City or township governments
Native American tribal governments (Federally recognized)
Private institutions of higher education
State governments
Special district governments
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments) - Additional Information on Eligibility
- Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/pa-files/PAR-14-107.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
National Institutes of Health 301-496-3405 - Similar Government Grants
- • Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowe...
- • Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
- • AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
- • Lethal Means Safety Suicide Prevention Research in Healthcare and Community Settings (R34 ...
- • Strategies to Improve Health Outcomes and Advance Health Equity in Rural Populations (R01 ...
- • Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...
- • Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...
- • Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
- More Grants from the National Institutes of Health
- • Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical ...
- • Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Mino...
- • Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowe...
- • NINDS Program Project Grant (P01 Clinical Trial Optional)
- • Centers for Research in Emerging Infectious Diseases (CREID) Network (U01 Clinical Trial N...